Structure via PubChem · Public domain (PubChem)
duvelisib
Sign in to saveAlso known as INK-1197, IPI-145
Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. It is taken by mouth. It is a PI3 kinase inhibitor.
Chemical data
- Formula
- C22H17ClN6O
- Molecular weight
- 416.9 g/mol
- IUPAC name
- 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2018
- Admin. routes
- oral
- Indications
- non-Hodgkins lymphoma, leukemia, rheumatoid arthritis, liver disease
via ChEMBL · EBI
~6 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- History
- Society and culture
- Legal status
- Synthesis
- References
- External links
Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. It is taken by mouth. It is a PI3 kinase inhibitor.
Common side effects include diarrhea, low white blood cells, rash, feeling tired, fever, and muscle pains. Other serious side effects include inflammation of the lungs and infections. It is a dual inhibitor of PI3Kδ and PI3Kγ.
Excerpted from Wikipedia’s “duvelisib” article, available under the CC BY-SA 4.0 licence.